NCT04021082 2023-02-21
CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)
Alexion Pharmaceuticals, Inc.
Phase 2/3 Withdrawn
Clinical Trials
3 trialsNCT00349518 2016-02-17
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Bristol-Myers Squibb
Phase 2/3 Withdrawn
NCT01326078 2014-03-26
Use of Lipid Emulsion or Nanoemulsion of Propofol on Children Undergoing Ambulatory Invasive Procedures.
CristĂĄlia Produtos QuĂmicos FarmacĂȘuticos Ltda.
Phase 2/3 Withdrawn